Cargando…

Use of direct-acting antiviral agents in hepatitis C virus-infected liver transplant candidates

Since the advent of direct acting antiviral (DAA) agents, chronic hepatitis C virus (HCV) treatment has evolved at a rapid pace. In contrast to prior regimen involving ribavirin and pegylated interferon, these newer agents are highly effective, well-tolerated, have shorter course of therapy and safe...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gadiparthi, Chiranjeevi, Cholankeril, George, Perumpail, Brandon J, Yoo, Eric R, Satapathy, Sanjaya K, Nair, Satheesh, Ahmed, Aijaz
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Baishideng Publishing Group Inc 2018
Materias:	Minireviews
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5776393/ https://www.ncbi.nlm.nih.gov/pubmed/29391754 http://dx.doi.org/10.3748/wjg.v24.i3.315

Ejemplares similares

Timing of Hepatitis C Virus Treatment in Liver Transplant Candidates in the Era of Direct-acting Antiviral Agents
por: Cholankeril, George, et al.
Publicado: (2017)

Direct Acting Antivirals in Patients with Chronic Hepatitis C and Down Syndrome
por: Yoo, Eric R., et al.
Publicado: (2016)

Pre-Operative Delta-MELD is an Independent Predictor of Higher Mortality following Liver Transplantation
por: Cholankeril, George, et al.
Publicado: (2019)

Expanding Treatment Access for Chronic Hepatitis C with Task-shifting in the Era of Direct-acting Antivirals
por: Yoo, Eric R., et al.
Publicado: (2017)

Rising Rates of Hepatocellular Carcinoma Leading to Liver Transplantation in Baby Boomer Generation with Chronic Hepatitis C, Alcohol Liver Disease, and Nonalcoholic Steatohepatitis-Related Liver Disease
por: Cholankeril, George, et al.
Publicado: (2017)

NAFLD Epidemiology, Emerging Pharmacotherapy, Liver Transplantation Implications and the Trends in the United States
por: Gadiparthi, Chiranjeevi, et al.
Publicado: (2020)

Underutilization of Hepatitis C Virus Seropositive Donor Kidneys in the United States in the Current Opioid Epidemic and Direct-Acting Antiviral Era
por: Li, Andrew A., et al.
Publicado: (2018)

Association between direct-acting antiviral agents in hepatitis C virus treatment and hepatocellular carcinoma occurrence and recurrence: The endless debate
por: Kamal, Ahmed, et al.
Publicado: (2022)

Reactivation of hepatitis B after liver transplantation: Current knowledge, molecular mechanisms and implications in management
por: Chauhan, Ranjit, et al.
Publicado: (2018)

Era of direct acting anti-viral agents for the treatment of hepatitis C
por: Ahmed, Monjur
Publicado: (2018)

Nonalcoholic Fatty Liver Disease: Epidemiology, Liver Transplantation Trends and Outcomes, and Risk of Recurrent Disease in the Graft
por: Liu, Andy, et al.
Publicado: (2018)

Challenges in the discontinuation of chronic hepatitis B antiviral agents
por: Kaewdech, Apichat, et al.
Publicado: (2021)

Direct-acting antivirals and hepatocellular carcinoma in chronic hepatitis C: A few lights and many shadows
por: Guarino, Maria, et al.
Publicado: (2018)

Retreatment of patients with treatment failure of direct-acting antivirals: Focus on hepatitis C virus genotype 1b
por: Kanda, Tatsuo, et al.
Publicado: (2017)

Hepatocellular carcinoma after direct-acting antiviral hepatitis C virus therapy: A debate near the end
por: Muzica, Cristina Maria, et al.
Publicado: (2020)

Non-alcoholic Fatty Liver Disease: A Review of Anti-diabetic Pharmacologic Therapies
por: Snyder, Heather S., et al.
Publicado: (2018)

Elastography as a predictor of liver cirrhosis complications after hepatitis C virus eradication in the era of direct-acting antivirals
por: Cerrito, Lucia, et al.
Publicado: (2021)

Safety of direct acting antiviral treatment for hepatitis C in oncologic setting: A clinical experience and a literature review
por: Spera, Anna Maria
Publicado: (2022)

Liver injury in COVID-19: The hepatic aspect of the respiratory syndrome — what we know so far
por: Anirvan, Prajna, et al.
Publicado: (2020)

Hepatic encephalopathy: what the multidisciplinary team can do
por: Liu, Andy, et al.
Publicado: (2017)

An Overview of Dietary Interventions and Strategies to Optimize the Management of Non-Alcoholic Fatty Liver Disease
por: Perumpail, Brandon J., et al.
Publicado: (2017)

Hepatitis C Virus in the Elderly in the Direct-Acting Antiviral Era: from Diagnosis to Cure
por: Mohammed Abdul, Mubeen Khan, et al.
Publicado: (2020)

The importance of a multidisciplinary approach to hepatocellular carcinoma
por: Siddique, Osama, et al.
Publicado: (2017)

Direct antiviral agents in hepatitis C virus related liver disease: Don’t count the chickens before they’re hatched
por: Compagnoni, Stella, et al.
Publicado: (2021)

Impact of direct acting antivirals on occurrence and recurrence of hepatocellular carcinoma: Biologically plausible or an epiphenomenon?
por: Butt, Amna Subhan, et al.
Publicado: (2018)

Mechanistic Potential and Therapeutic Implications of Cannabinoids in Nonalcoholic Fatty Liver Disease
por: Dibba, Pratima, et al.
Publicado: (2018)

The Role of Direct-acting Antivirals in the Treatment of Children with Chronic Hepatitis C
por: Yang, Christine Hong Ting, et al.
Publicado: (2017)

Association of non-alcoholic fatty liver disease and COVID-19: A literature review of current evidence
por: Anirvan, Prajna, et al.
Publicado: (2021)

The Role of Cannabinoids in the Setting of Cirrhosis
por: Dibba, Pratima, et al.
Publicado: (2018)

Judicious Use of Lipid Lowering Agents in the Management of NAFLD
por: Iqbal, Umair, et al.
Publicado: (2018)

Clinical epidemiology and disease burden of nonalcoholic fatty liver disease
por: Perumpail, Brandon J, et al.
Publicado: (2017)

Optimizing the Nutritional Support of Adult Patients in the Setting of Cirrhosis
por: Perumpail, Brandon J., et al.
Publicado: (2017)

Discontinuation of antiviral therapy in chronic hepatitis B patients
por: Medas, Renato, et al.
Publicado: (2021)

Fibrosis regression following hepatitis C antiviral therapy
por: Elsharkawy, Aisha, et al.
Publicado: (2022)

Antiviral treatment for chronic hepatitis B: Safety, effectiveness, and prognosis
por: Wu, Ya-Li, et al.
Publicado: (2019)

Marine sulfated polysaccharides as potential antiviral drug candidates to treat Corona Virus disease (COVID-19)
por: Andrew, Monic, et al.
Publicado: (2021)

Hepatitis C-related hepatocellular carcinoma in the era of new generation antivirals
por: Baumert, Thomas F., et al.
Publicado: (2017)

Older candidates for kidney transplantation: Who to refer and what to expect?
por: Concepcion, Beatrice P, et al.
Publicado: (2016)

Hepatitis B in renal transplant patients
por: Marinaki, Smaragdi, et al.
Publicado: (2017)

Assessing the Safety of Direct-Acting Antiviral Agents for Hepatitis C
por: McGlynn, Elizabeth A., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_2k4spuamtqvtdeovmki4uj6cst